5445582025-07-012025-09-305445582025-09-305445582025-03-315445582025-04-012025-09-305445582025-07-012025-09-30in-capmkt:OtherExpenses1Member5445582025-07-012025-09-30in-capmkt:OtherExpenses2Member5445582025-07-012025-09-30in-capmkt:OtherExpenses3Member5445582025-07-012025-09-30in-capmkt:OtherExpenses4Member5445582025-07-012025-09-30in-capmkt:OtherExpenses5Member5445582025-07-012025-09-30in-capmkt:OtherExpenses6Member5445582025-07-012025-09-30in-capmkt:OtherExpenses7Member5445582025-07-012025-09-30in-capmkt:OtherExpenses8Member5445582025-07-012025-09-30in-capmkt:OtherExpenses9Member5445582025-07-012025-09-30in-capmkt:OtherExpenses10Member5445582025-04-012025-09-30in-capmkt:OtherExpenses1Member5445582025-04-012025-09-30in-capmkt:OtherExpenses2Member5445582025-04-012025-09-30in-capmkt:OtherExpenses3Member5445582025-04-012025-09-30in-capmkt:OtherExpenses4Member5445582025-04-012025-09-30in-capmkt:OtherExpenses5Member5445582025-04-012025-09-30in-capmkt:OtherExpenses6Member5445582025-04-012025-09-30in-capmkt:OtherExpenses7Member5445582025-04-012025-09-30in-capmkt:OtherExpenses8Member5445582025-04-012025-09-30in-capmkt:OtherExpenses9Member5445582025-04-012025-09-30in-capmkt:OtherExpenses10Member5445582025-07-012025-09-30in-capmkt:ReportableSegments1Member5445582025-07-012025-09-30in-capmkt:ReportableSegments2Member5445582025-07-012025-09-30in-capmkt:ReportableSegments3Member5445582025-07-012025-09-30in-capmkt:ReportableSegments4Member5445582025-07-012025-09-30in-capmkt:ReportableSegments5Member5445582025-07-012025-09-30in-capmkt:ReportableSegments6Member5445582025-07-012025-09-30in-capmkt:ReportableSegments7Member5445582025-07-012025-09-30in-capmkt:ReportableSegments8Member5445582025-04-012025-09-30in-capmkt:ReportableSegments1Member5445582025-04-012025-09-30in-capmkt:ReportableSegments2Member5445582025-04-012025-09-30in-capmkt:ReportableSegments3Member5445582025-04-012025-09-30in-capmkt:ReportableSegments4Member5445582025-04-012025-09-30in-capmkt:ReportableSegments5Member5445582025-04-012025-09-30in-capmkt:ReportableSegments6Member5445582025-04-012025-09-30in-capmkt:ReportableSegments7Member5445582025-04-012025-09-30in-capmkt:ReportableSegments8Member5445582025-07-012025-09-30in-capmkt:ReportableSegments1Member5445582025-07-012025-09-30in-capmkt:ReportableSegments2Member5445582025-07-012025-09-30in-capmkt:ReportableSegments3Member5445582025-07-012025-09-30in-capmkt:ReportableSegments4Member5445582025-07-012025-09-30in-capmkt:ReportableSegments5Member5445582025-07-012025-09-30in-capmkt:ReportableSegments6Member5445582025-07-012025-09-30in-capmkt:ReportableSegments7Member5445582025-07-012025-09-30in-capmkt:ReportableSegments8Member5445582025-04-012025-09-30in-capmkt:ReportableSegments1Member5445582025-04-012025-09-30in-capmkt:ReportableSegments2Member5445582025-04-012025-09-30in-capmkt:ReportableSegments3Member5445582025-04-012025-09-30in-capmkt:ReportableSegments4Member5445582025-04-012025-09-30in-capmkt:ReportableSegments5Member5445582025-04-012025-09-30in-capmkt:ReportableSegments6Member5445582025-04-012025-09-30in-capmkt:ReportableSegments7Member5445582025-04-012025-09-30in-capmkt:ReportableSegments8Member5445582025-07-012025-09-30in-capmkt:ReportableSegments1Member5445582025-09-30in-capmkt:ReportableSegments1Member5445582025-07-012025-09-30in-capmkt:ReportableSegments2Member5445582025-09-30in-capmkt:ReportableSegments2Member5445582025-07-012025-09-30in-capmkt:ReportableSegments3Member5445582025-09-30in-capmkt:ReportableSegments3Member5445582025-07-012025-09-30in-capmkt:ReportableSegments4Member5445582025-09-30in-capmkt:ReportableSegments4Member5445582025-07-012025-09-30in-capmkt:ReportableSegments5Member5445582025-09-30in-capmkt:ReportableSegments5Member5445582025-07-012025-09-30in-capmkt:ReportableSegments6Member5445582025-09-30in-capmkt:ReportableSegments6Member5445582025-07-012025-09-30in-capmkt:ReportableSegments7Member5445582025-09-30in-capmkt:ReportableSegments7Member5445582025-07-012025-09-30in-capmkt:ReportableSegments8Member5445582025-09-30in-capmkt:ReportableSegments8Member5445582025-07-012025-09-30in-capmkt:ReportableSegments1Member5445582025-09-30in-capmkt:ReportableSegments1Member5445582025-07-012025-09-30in-capmkt:ReportableSegments2Member5445582025-09-30in-capmkt:ReportableSegments2Member5445582025-07-012025-09-30in-capmkt:ReportableSegments3Member5445582025-09-30in-capmkt:ReportableSegments3Member5445582025-07-012025-09-30in-capmkt:ReportableSegments4Member5445582025-09-30in-capmkt:ReportableSegments4Member5445582025-07-012025-09-30in-capmkt:ReportableSegments5Member5445582025-09-30in-capmkt:ReportableSegments5Member5445582025-07-012025-09-30in-capmkt:ReportableSegments6Member5445582025-09-30in-capmkt:ReportableSegments6Member5445582025-07-012025-09-30in-capmkt:ReportableSegments7Member5445582025-09-30in-capmkt:ReportableSegments7Member5445582025-07-012025-09-30in-capmkt:ReportableSegments8Member5445582025-09-30in-capmkt:ReportableSegments8Member5445582025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15445582025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares544558FABTECHNOTLISTEDINE0HF201011Fabtech Technologies LimitedMain BoardEquity2025-04-012026-03-312025-10-272025-10-23INRLakhsQuarterlySecond quarterGeographical2025-10-2716:00:002025-10-2723:00:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated12148070002795400012427610000404821000148926000903120001067600013077000266198000934010000308751000030875100039200000-76610003153900002772120000003849000281061000-3370002807240002810610000-337000280724000323922000108.688.68008.688.681.The consolidated financial results of Fabtech Technologies Limited (the "Company") has been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (the"Act") and other accounting principles generally accepted in India and presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") ' ' These results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on October 27, 2025. ' ' In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Limited review of the consolidated results of quarter and half year ended September 30, 2025 has been carried out by the Statutory Auditors. ' ' 2.Previous Year's/Period's figures have been regrouped/rearranged/adjusted/rectified wherever considered necessary. ' ' 3.The figures for the year ended March 31, 2025 have been extracted from the consolidated financial statements which were audited by the Statutory Auditors of the Company. ' The figures for the corresponding quarter and half year ended September 30, 2024 and have not been subjected to a review or audit by the Statutory Auditors, However, the management has exercised necessary care to ensure that the standalone financial results for that period are fairly stated. These figures are furnished by the mangement of the Company and were reviewed and recommended by the Audit committee and approved by the Board of Directors at their meeting held on October 27, 2025. ' ' 4.Subsequent to the quarter ended September 30, 2025, the Company has completed its initial public offer (IPO) of fresh issue of 1,20,60,000 equity shares of face value of Rs.10 each at an issue price of Rs.191. The equity shares of the Company were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on October 7, 2025. The Company will provide an update on the utilisation of IPO proceeds towards the objects of the fresh issue effective from next reporting period based on actual utilisation of the funds pursuant to the IPO. ' ' 5.The reportable segments derives their revenues from turnkey projects solution provided to pharmaceuticals and allied industries by way of supplying pharmaceutical machineries / equipment,inhouse designing and engineering and to undertake other activities requiredinvarious pharmaceutical turnkeyprojects. The CODM reviews geographical revenue as the performance indicator. The measurement of geographical segment's revenues and assets is consistent with the accounting policies that are used in preparation of the Group's Consolidated Financial Results. The same is attached herewith as Annexure A to the Unaudited Consolidated Financial Results. ' ' 6.The exceptional item amounting to Rs. 177.49 Lakhs disclosed in the profit or loss statement for the half year ended September 30, 2025 and quarter ended June 30, 2025, represents the profit arising from the sale of 51% stake in the subsidiary LLP. Prior to the transaction, the Company held 99.99% ownership interest in the Subsidiary LLP. Post Sale, the Company's ownership interest has reduced to 48.99%. This transaction is significant and non-recurring in nature and has been presented separately as an exceptional item to provide clarity and transparency to the users of the financial results. ' ' 7.The exceptional item amounting to Rs. 1,784.86 Lakhs disclosed in the Statement of Profit and Loss for the quarter ended June 30, 2024, represents the profit arising from the sale of a equity stake in the associate. Prior to this transaction, the Company held a 33.33% ownership interest in the associate. Post-sale, the Company's ownership has reduced to 16.33%, which has been classified as "Asset Held for Sale" as disclosed in the audited financial statements for the year ended March 31, 2025. This transaction is significant and non-recurring in nature and has therefore been presented separately as an exceptional item to ensure greater clarity and transparency for users of the financial statements. ' ' 8.The unaudited consolidated financial results are also being made available on the Stock Exchange websites www.bseindia.com and www.nseindia.com and on the Company's website: www.fabtechnologies.com.2025-04-012025-09-30UnauditedConsolidated18948750003740500019322800000763923000220411000195491000240870002700800047263300017035530002287270001774900024647600045668000-148170003085100002156250000004177000219802000-6730002191290002198020001000-673000219129000323922000106.796.79006.796.79Project erection and commissioning expenses78301000Business Promotion and Advertising22212000Travelling and Conveyance expenses 28753000Freight and forwarding 86802000Provision for Doubtful Debt and advances 18071000Legal and professional charges 10910000Rent7346000Bank Charges 4419000Communication Expenses 2922000Other Expenses 6462000Project erection and commissioning expenses124977000Business Promotion and Advertising40090000Travelling and Conveyance expenses 61632000Freight and forwarding 162139000Provision for Doubtful Debt and advances 20992000Legal and professional charges 19521000Rent14500000Bank Charges 6187000Communication Expenses 5268000Other Expenses 17327000286813000222097000549900015948400084855000613310003056700003101600027557800011266730002551930009464900015465540002217010001929020001968000197811000225558500004813080002992086000563350000417509400032392200016244110001948333000-10001948332000378400025929800026308200015283000278365000140146000134645000362336000496981000876330007247600001182822000743800033377000194839700022267620004175094000UAE471821000Saudi Arabia315710000Egypt19047000India85438000Sri Lanka1224000Algeria16156000Kenya27272000Rest of the World499861000UAE874242000Saudi Arabia390105000Egypt63400000India192460000Sri Lanka5908000Algeria25962000Kenya27272000Rest of the World6100320001436529000218938100014365290002189381000UAE0Saudi Arabia0Egypt0India0Sri Lanka0Algeria0Kenya0Rest of the World0UAE0Saudi Arabia0Egypt0India0Sri Lanka0Algeria0Kenya0Rest of the World00000UAE177236000Saudi Arabia468660000Egypt11968000India245608000Sri Lanka34904000Algeria32624000Kenya28620000Rest of the World584962000158458200001584582000UAE0Saudi Arabia0Egypt0India0Sri Lanka0Algeria0Kenya0Rest of the World000024051000338966000-658330000-292766000001188800000-492071000055331500002700800005784000066801000045490000140330000-30400000-11000022670000273867000520343000000714120000448931000935480000027353000000011000234920000000000000000000001353000006704300012328700000000000-402275000027456000000-11342000-441073000131145000013114500090556000221701000Remeasurement gain/(loss) of defined benefit plans-450000-450000Remeasurement gain/(loss) of defined benefit plans-900000-900000-113000-227000-337000-673000